Insider · CIK 0002017800
Nikolay Savchuk
Files at TRAW (Onconova Therapeutics, Inc.), Lomond Therapeutics Holdings, Inc.. First filing -, latest -.
In brief
Nikolay Savchuk files SEC Form 4 as COO, president, director and 10% owner at TRAW (Onconova Therapeutics, Inc.), and also at Lomond Therapeutics Holdings, Inc.. No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Nikolay Savchuk has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 13 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 9, 2026 | TRAW Onconova Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +93,000 | $0.00 | $0 | 93,000 | Jul 15, 2026 |
| Mar 8, 2026 | TRAW Onconova Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +96,899 | $0.00 | $0 | 96,899 | Mar 10, 2026 |
| Dec 12, 2025 | TRAW Onconova Therapeutics, Inc. | AGrant or award Common Stock | +16,419 | $0.00 | $0 | 150,606 | Dec 16, 2025 |
| Dec 12, 2025 | TRAW Onconova Therapeutics, Inc. | AGrant or award Stock Option (right to purchase)derivative | +65,676 | $0.00 | $0 | 65,676 | Dec 16, 2025 |
| Oct 12, 2025 | TRAW Onconova Therapeutics, Inc. | AGrant or award Stock Option (right to purchase)derivative | +22,435 | $0.00 | $0 | 22,435 | Oct 15, 2025 |
| Apr 2, 2025 | TRAW Onconova Therapeutics, Inc. | JOther Common Stock | -605,531 | - | - | 0 | Apr 8, 2025 |
| Apr 2, 2025 | TRAW Onconova Therapeutics, Inc. | JOther Series C Preferred Stockderivative | -2,264 | $0.00 | $0 | 0 | Apr 8, 2025 |
| Nov 1, 2024 | - Lomond Therapeutics Holdings, Inc. | CConversion Common Stockindirect: By TPAV, LLC | +539,062 | $3.20 | $1.7M | 539,062 | Nov 5, 2024 |
| Nov 1, 2024 | - Lomond Therapeutics Holdings, Inc. | CConversion Common Stockindirect: By TPAV, LLC | +694,444 | $3.60 | $2.5M | 1,233,506 | Nov 5, 2024 |
| Nov 1, 2024 | - Lomond Therapeutics Holdings, Inc. | AGrant or award Common Stockindirect: By TPAV, LLC | +1,443,750 | $4.00 | $5.8M | 2,677,256 | Nov 5, 2024 |
| Nov 1, 2024 | - Lomond Therapeutics Holdings, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +1,258,000 | $0.00 | $0 | 1,258,000 | Nov 5, 2024 |
| Nov 1, 2024 | - Lomond Therapeutics Holdings, Inc. | CConversion Simple Agreement for Future Equityderivativeindirect: By TPAV, LLC | +539,062 | $0.00 | $0 | 0 | Nov 5, 2024 |
| Nov 1, 2024 | - Lomond Therapeutics Holdings, Inc. | CConversion Simple Agreement for Future Equityderivativeindirect: By TPAV, LLC | +694,444 | $0.00 | $0 | 0 | Nov 5, 2024 |
Questions about Nikolay Savchuk
Answered from the filings on this page, as of the latest one.
Is Nikolay Savchuk buying or selling?
Nikolay Savchuk has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Nikolay Savchuk's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Nikolay Savchuk has 0.
Where does Nikolay Savchuk file Form 4?
Nikolay Savchuk has filed Form 4 at TRAW (Onconova Therapeutics, Inc.) as Chief Operating Officer; Lomond Therapeutics Holdings, Inc. as President and COO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.